Evidence map›Paper›PMID 30467600›Full record

ArticleVirchows Archiv : an international journal of pathology2019

Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.

Marta Brunetti, Arild Holth, Ioannis Panagopoulos, Anne Cathrine Staff, Francesca Micci, Ben Davidson

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. A Photocaged N-Phosphonopiperidinone as a Selective Photo-Cleavable DPP8/9 Inhibitor.Chembiochem : a European journal of chemical biology · 2025
    Article
  3. Article
  4. Identification of a Novel Oncogenic Fusion GeneInternational journal of molecular sciences · 2022
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Fusion of theCancer genomics & proteomics
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marta BrunettiDepartment of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310, Oslo, Norway.
Arild HolthDepartment of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310, Oslo, Norway.
Ioannis PanagopoulosSection for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Norwegian Radium Hospital, Oslo University Hospital, N-0310, Oslo, Norway.
Anne Cathrine StaffFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, N-0316, Oslo, Norway.
Francesca MicciSection for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Norwegian Radium Hospital, Oslo University Hospital, N-0310, Oslo, Norway.
Ben DavidsonDepartment of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310, Oslo, Norway. bend@medisin.uio.no.ORCID http://orcid.org/0000-0003-3332-8427
Oslo University Hospital · NO

Funding

The Inger and John Fredriksen Foundation for Ovarian Cancer Research. NoneThe South-East Health Region of Norway None
6 · The paper itself

Abstract

Dipeptidyl peptidase 9 (DPP9) was recently identified as fusion gene in ovarian high-grade serous carcinoma (HGSC). The aim of this study was to analyze the expression and clinical relevance of DPP8 and DPP9 in ovarian carcinoma, with focus on HGSC. mRNA expression by qRT-PCR of DPP8 and DPP9 was analyzed in 232 carcinomas, including 114 effusions and 118 surgical specimens (89 ovarian, 29 solid metastases). DPP8 and DPP9 protein expression was analyzed in 92 effusions. DPP8 and DPP9 mRNA was overexpressed in effusions compared to solid lesions in analysis of all histotypes (p < 0.001 both), as well as in analysis limited to HGSC (p < 0.001 for DPP9, p = 0.002 for DPP8). DPP9 mRNA was additionally overexpressed in HGSC compared to other histotypes (p = 0.021). DPP8 and DPP9 protein was expressed in carcinoma cells in 31/92 (37%) and 81/92 (88%) effusions, respectively. DPP8 protein expression in HGSC effusions was significantly related to better (complete) chemoresponse at diagnosis (p = 0.005). DPP8 and DPP9 mRNA and protein expression was unrelated to survival in analysis of the entire effusion cohort. However, higher DPP9 mRNA levels were significantly related to longer overall survival in pre-chemotherapy effusions (p = 0.049). In conclusion, DPP8 and DPP9 mRNA is frequently expressed in ovarian carcinoma, whereas DPP9 is more frequently expressed at the protein level. DPP8 and DPP9 may be related to less aggressive disease in advanced-stage HGSC.

Indexed as

Cohort StudiesCystadenocarcinoma, SerousDipeptidasesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDisease-Free SurvivalDisease ProgressionFemaleGene Expression ProfilingHumansImmunohistochemistryKaplan-Meier EstimateOvarian NeoplasmsRNA, MessengerDipeptidasesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDPP8 protein, humanDPP9 protein, humanRNA, MessengerDipeptidyl peptidasesDisease progressionImmunohistochemistryOvarian carcinomaQuantitative PCRSurvival

Identifiers

PMID30467600
OpenAlexW2900843289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.